Related references
Note: Only part of the references are listed.Adenosine A2Areceptor antagonists: from caffeine to selective non-xanthines
Kenneth A. Jacobson et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson's Disease: A Recent Update and Challenge
Jiyue Zheng et al.
ACS CHEMICAL NEUROSCIENCE (2019)
A2B Adenosine Receptor and Cancer
Zhan-Guo Gao et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers
Lisa Seitz et al.
INVESTIGATIONAL NEW DRUGS (2019)
Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer
Mohammad H. Kazemi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging
Aren van Waarde et al.
MEDICINAL RESEARCH REVIEWS (2018)
Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models
Robert D. Leone et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Allosteric Coupling of Drug Binding and Intracellular Signaling in the A(2A) Adenosine Receptor
Matthew T. Eddy et al.
CELL (2018)
AB928, a dual antagonist of the A 2a R and A 2b R adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy
U. Schindler et al.
EUROPEAN JOURNAL OF CANCER (2018)
A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression
Jorgen Kjaergaard et al.
JOURNAL OF IMMUNOLOGY (2018)
Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals
Prakash Rucktooa et al.
SCIENTIFIC REPORTS (2018)
Enabling STD-NMR fragment screening using stabilized native GPCR: A case study of adenosine receptor
Sebastien Igonet et al.
SCIENTIFIC REPORTS (2018)
A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models
Stephen B. Willingham et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Targeting adenosine A2A receptor antagonism for treatment of cancer
Miles Congreve et al.
EXPERT OPINION ON DRUG DISCOVERY (2018)
A(2A) adenosine receptor functional states characterized by F-19-NMR
Lukas Susac et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
PBF509, an Adenosine A2A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders
Fabiana Nunez et al.
FRONTIERS IN PHARMACOLOGY (2018)
Phase I/II Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (pts) with Advanced NSCLC
A. Chiappori et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket
Bingfa Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment
Melanie Mediavilla-Varela et al.
NEOPLASIA (2017)
Targeting immunosuppressive adenosine in cancer
D. Vijayan et al.
NATURE REVIEWS CANCER (2017)
Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis
Arabella Young et al.
CANCER RESEARCH (2017)
Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression
Alexandra Borodovsky et al.
CANCER RESEARCH (2017)
A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer
Stephen M. Hatfield et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
Role of adenosine A2b receptor overexpression in tumor progression
Cesar Sepulveda et al.
LIFE SCIENCES (2016)
Structure of the adenosine A2A receptor bound to an engineered G protein
Byron Carpenter et al.
NATURE (2016)
Medicinal chemistry of adenosine, P2Y and P2X receptors
Kenneth A. Jacobson et al.
NEUROPHARMACOLOGY (2016)
The prognostic value of regadenoson myocardial perfusion imaging
Fadi G. Hage et al.
JOURNAL OF NUCLEAR CARDIOLOGY (2015)
Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model
Claudia Sorrentino et al.
ONCOTARGET (2015)
Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses
Paul A. Beavis et al.
CANCER IMMUNOLOGY RESEARCH (2015)
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
Robert D. Leone et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2015)
Adenosine A2A Receptors Intrinsically Regulate CD8+ T Cells in the Tumor Microenvironment
Caglar Cekic et al.
CANCER RESEARCH (2014)
Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
Deepak Mittal et al.
CANCER RESEARCH (2014)
Binding Kinetics of ZM241385 Derivatives at the Human Adenosine A2A Receptor
Dong Guo et al.
CHEMMEDCHEM (2014)
Adenosine A2A Receptor Antagonists in Parkinson's Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
Annalisa Pinna
CNS DRUGS (2014)
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2014)
Istradefylline: First Global Approval
Rosselle Dungo et al.
DRUGS (2013)
The Novel HDAC Inhibitor OBP-801/YM753 Enhances the Effects of 5-Fluorouracil With Radiation on Esophageal Squamous Carcinoma Cells
Akinobu Furutani et al.
ONCOLOGY RESEARCH (2013)
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Sherene Loi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors
Paul A. Beavis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design
Miles Congreve et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Anti-inflammatory effects of purine nucleosides, adenosine and inosine, in a mouse model of pleurisy: evidence for the role of adenosine A2 receptors
Fernanda da Rocha Lapa et al.
PURINERGIC SIGNALLING (2012)
The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway
Akio Ohta et al.
FRONTIERS IN IMMUNOLOGY (2012)
Adenosine A2A Receptor Antagonists and Parkinson's Disease
Brian C. Shook et al.
ACS CHEMICAL NEUROSCIENCE (2011)
Activation of Adenosine A2A Receptor Up-Regulates BDNF Expression in Rat Primary Cortical Neurons
Se Jin Jeon et al.
NEUROCHEMICAL RESEARCH (2011)
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors-An Update
Bertil B. Fredholm et al.
PHARMACOLOGICAL REVIEWS (2011)
Structure of an Agonist-Bound Human A2A Adenosine Receptor
Fei Xu et al.
SCIENCE (2011)
Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine
Andrew S. Dore et al.
STRUCTURE (2011)
Regadenoson
Karly P. Garnock-Jones et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2010)
Antagonists of the Human A2A Adenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidines
Roger J. Gillespie et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression
Robert A. Hodgson et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Adenosine A2A receptor is a unique angiogenic target of HIF-2α in pulmonary endothelial cells
Aftab Ahmad et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Adenosine receptors:: therapeutic aspects for inflammatory and immune diseases
Gyorgy Hasko et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist
Veli-Pekka Jaakola et al.
SCIENCE (2008)
Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists
Ming Yang et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2007)
Potent, selective, and orally active adenosine A2A receptor antagonists:: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
Bernard R. Neustadt et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
A2A adenosine receptor protects tumors from antitumor T cells
Akio Ohta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists
E Kiselgof et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Kinetic and functional properties of [3H]ZM241385, a high affinity antagonist for adenosine A2A receptors
A Uustare et al.
LIFE SCIENCES (2005)
Adenosine receptors: G protein-mediated signalling and the role of accessory proteins
M Klinger et al.
CELLULAR SIGNALLING (2002)
Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage
A Ohta et al.
NATURE (2001)
Share Paper
